$4.55
0.87% yesterday
NYSE, May 28, 10:00 pm CET
ISIN
CA0717341071
Symbol
BHC
Sector
Industry

Bausch Health Companies Inc. Stock price

$4.55
-0.86 15.90% 1M
-3.57 43.97% 6M
-3.51 43.55% YTD
-1.65 26.61% 1Y
-5.32 53.90% 3Y
-14.03 75.51% 5Y
-237.18 98.12% 10Y
NYSE, Closing price Wed, May 28 2025
-0.04 0.87%
ISIN
CA0717341071
Symbol
BHC
Sector
Industry

Key metrics

Market capitalization $1.67b
Enterprise Value $22.04b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 18.13
EV/Sales (TTM) EV/Sales 2.27
P/S ratio (TTM) P/S ratio 0.17
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 8.53%
Revenue (TTM) Revenue $9.73b
EBIT (operating result TTM) EBIT $1.85b
Free Cash Flow (TTM) Free Cash Flow $1.22b
Cash position $1.13b
EPS (TTM) EPS $-0.11
P/E forward 6.85
P/S forward 0.17
EV/Sales forward 2.20
Short interest 2.88%
Show more

Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Bausch Health Companies Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Bausch Health Companies Inc. forecast:

5x Hold
83%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Bausch Health Companies Inc. forecast:

Hold
83%
Sell
17%

Financial data from Bausch Health Companies Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9,731 9,731
9% 9%
100%
- Direct Costs 2,843 2,843
9% 9%
29%
6,888 6,888
8% 8%
71%
- Selling and Administrative Expenses 3,369 3,369
13% 13%
35%
- Research and Development Expense 608 608
1% 1%
6%
2,911 2,911
6% 6%
30%
- Depreciation and Amortization 1,059 1,059
2% 2%
11%
EBIT (Operating Income) EBIT 1,852 1,852
11% 11%
19%
Net Profit -40 -40
91% 91%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bausch Health Companies Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galder...
Neutral
Business Wire
8 days ago
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye d...
Neutral
Accesswire
14 days ago
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J.
More Bausch Health Companies Inc. News

Company Profile

Manufactures and markets pharmaceutical products

Head office Canada
CEO Thomas Appio
Employees 20,700
Founded 1994
Website www.bauschhealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today